Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma

NCT01832727 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT01832727
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01832727 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma
Lead sponsor
Amgen
Phase
Phase 1/2
Overall status
Terminated
Start date
July 2, 2013
Completion date
June 25, 2019
Enrollment
65 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma